Bristol-Myers Squibb and Pfizer have entered into a collaboration with Portola Pharmaceuticals to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, in Phase III development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).   Portola will receive $15 million upfront, regulatory milestones of $20 million and sales milestones of $70 million, as well as compensation based on an...